Barclays PLC Acquires 31,057 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Barclays PLC lifted its holdings in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 162.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 50,210 shares of the company’s stock after purchasing an additional 31,057 shares during the period. Barclays PLC owned about 0.15% of Lexeo Therapeutics worth $454,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in shares of Lexeo Therapeutics by 86.5% during the third quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock valued at $5,003,000 after buying an additional 256,635 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in Lexeo Therapeutics during the 3rd quarter valued at about $11,307,000. Jane Street Group LLC grew its position in Lexeo Therapeutics by 33.3% during the 3rd quarter. Jane Street Group LLC now owns 35,677 shares of the company’s stock worth $323,000 after acquiring an additional 8,918 shares during the last quarter. Wellington Management Group LLP grew its position in Lexeo Therapeutics by 134.8% during the 3rd quarter. Wellington Management Group LLP now owns 51,892 shares of the company’s stock worth $469,000 after acquiring an additional 29,791 shares during the last quarter. Finally, State Street Corp increased its stake in Lexeo Therapeutics by 29.4% in the 3rd quarter. State Street Corp now owns 253,946 shares of the company’s stock worth $2,296,000 after purchasing an additional 57,674 shares during the period. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on LXEO shares. HC Wainwright increased their price objective on Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. Leerink Partners dropped their price target on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday, November 13th. Finally, Chardan Capital boosted their price objective on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Lexeo Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $23.80.

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO opened at $5.07 on Friday. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm’s fifty day simple moving average is $6.87 and its 200 day simple moving average is $9.52. The stock has a market cap of $167.66 million, a P/E ratio of -1.60 and a beta of 3.08. Lexeo Therapeutics, Inc. has a twelve month low of $4.78 and a twelve month high of $22.33.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.